Latest News & Insights
Stay Up to Date with Our Community
Featured
Targeting clinically validated pathways to enable patients to achieve freedom from migraine
Targeting clinically validated pathways to enable patients to achieve freedom from...
Star Therapeutics to receive $1.25 billion upfront, with up to $750...
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1...
Company announces $30 million Series A financing and founding leadership team...
Veteran biopharma leader joins to help lead Kyverna’s next phase of...
REX-8756 is an oral, first-in-class orthosteric STAT6 inhibitor currently being evaluated...
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial...
Provides corporate update including appointment of gene therapy expert Romuald Corbau,...
Phase 1 study builds on early signals of anti-tumor activity in...